216 related articles for article (PubMed ID: 21454924)
1. miRNA signature of schwannomas: possible role(s) of "tumor suppressor" miRNAs in benign tumors.
Erkan EP; Breakefield XO; Saydam O
Oncotarget; 2011 Mar; 2(3):265-70. PubMed ID: 21454924
[TBL] [Abstract][Full Text] [Related]
2. miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways.
Saydam O; Senol O; Würdinger T; Mizrak A; Ozdener GB; Stemmer-Rachamimov AO; Yi M; Stephens RM; Krichevsky AM; Saydam N; Brenner GJ; Breakefield XO
Cancer Res; 2011 Feb; 71(3):852-61. PubMed ID: 21156648
[TBL] [Abstract][Full Text] [Related]
3. The neurofibromatosis type 2 gene is inactivated in schwannomas.
Twist EC; Ruttledge MH; Rousseau M; Sanson M; Papi L; Merel P; Delattre O; Thomas G; Rouleau GA
Hum Mol Genet; 1994 Jan; 3(1):147-51. PubMed ID: 8162016
[TBL] [Abstract][Full Text] [Related]
4. PAK1 inhibition reduces tumor size and extends the lifespan of mice in a genetically engineered mouse model of Neurofibromatosis Type 2 (NF2).
Hawley E; Gehlhausen J; Karchugina S; Chow HY; Araiza-Olivera D; Radu M; Smith A; Burks C; Jiang L; Li X; Bessler W; Masters A; Edwards D; Burgin C; Jones D; Yates C; Clapp DW; Chernoff J; Park SJ
Hum Mol Genet; 2021 Aug; 30(17):1607-1617. PubMed ID: 34075397
[TBL] [Abstract][Full Text] [Related]
5. Combined molecular genetic studies of chromosome 22q and the neurofibromatosis type 2 gene in central nervous system tumors.
Ng HK; Lau KM; Tse JY; Lo KW; Wong JH; Poon WS; Huang DP
Neurosurgery; 1995 Oct; 37(4):764-73. PubMed ID: 8559307
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of chromosome 22 deletions in schwannomas.
Bijlsma EK; Brouwer-Mladin R; Bosch DA; Westerveld A; Hulsebos TJ
Genes Chromosomes Cancer; 1992 Oct; 5(3):201-5. PubMed ID: 1384671
[TBL] [Abstract][Full Text] [Related]
7. A group of schwannomas with interstitial deletions on 22q located outside the NF2 locus shows no detectable mutations in the NF2 gene.
Bruder CE; Ichimura K; Tingby O; Hirakawa K; Komatsuzaki A; Tamura A; Yuasa Y; Collins VP; Dumanski JP
Hum Genet; 1999 May; 104(5):418-24. PubMed ID: 10394935
[TBL] [Abstract][Full Text] [Related]
8. cDNA microarray analysis of vestibular schwannomas.
Welling DB; Lasak JM; Akhmametyeva E; Ghaheri B; Chang LS
Otol Neurotol; 2002 Sep; 23(5):736-48. PubMed ID: 12218628
[TBL] [Abstract][Full Text] [Related]
9. Analysis of mutations in the SCH gene in schwannomas.
Bijlsma EK; Merel P; Bosch DA; Westerveld A; Delattre O; Thomas G; Hulsebos TJ
Genes Chromosomes Cancer; 1994 Sep; 11(1):7-14. PubMed ID: 7529050
[TBL] [Abstract][Full Text] [Related]
10. Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors.
Tahiri A; Leivonen SK; Lüders T; Steinfeld I; Ragle Aure M; Geisler J; Mäkelä R; Nord S; Riis ML; Yakhini Z; Kleivi Sahlberg K; Børresen-Dale AL; Perälä M; Bukholm IR; Kristensen VN
Carcinogenesis; 2014 Jan; 35(1):76-85. PubMed ID: 24104550
[TBL] [Abstract][Full Text] [Related]
11. Mutational analysis and expression studies of the neurofibromatosis type 2 (NF2) gene in a patient with a ring chromosome 22 and NF2.
Kehrer-Sawatzki H; Udart M; Krone W; Baden R; Fahsold R; Thomas G; Schmucker B; Assum G
Hum Genet; 1997 Jul; 100(1):67-74. PubMed ID: 9225971
[TBL] [Abstract][Full Text] [Related]
12. A step-by-step microRNA guide to cancer development and metastasis.
Markopoulos GS; Roupakia E; Tokamani M; Chavdoula E; Hatziapostolou M; Polytarchou C; Marcu KB; Papavassiliou AG; Sandaltzopoulos R; Kolettas E
Cell Oncol (Dordr); 2017 Aug; 40(4):303-339. PubMed ID: 28748501
[TBL] [Abstract][Full Text] [Related]
13. Clinical manifestations of mutations in the neurofibromatosis type 2 gene in vestibular schwannomas (acoustic neuromas).
Welling DB
Laryngoscope; 1998 Feb; 108(2):178-89. PubMed ID: 9473065
[TBL] [Abstract][Full Text] [Related]
14. Segmental neurofibromatosis type 2: discriminating two hit from four hit in a patient presenting multiple schwannomas confined to one limb.
Castellanos E; Bielsa I; Carrato C; Rosas I; Solanes A; Hostalot C; Amilibia E; Prades J; Roca-Ribas F; Lázaro C; Blanco I; Serra E;
BMC Med Genomics; 2015 Jan; 8():2. PubMed ID: 25739810
[TBL] [Abstract][Full Text] [Related]
15. [Neurofibromatosis type 2].
Goutagny S; Bouccara D; Bozorg-Grayeli A; Sterkers O; Kalamarides M
Rev Neurol (Paris); 2007 Sep; 163(8-9):765-77. PubMed ID: 17878803
[TBL] [Abstract][Full Text] [Related]
16. Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function.
Kley N; Whaley J; Seizinger BR
Glia; 1995 Nov; 15(3):297-307. PubMed ID: 8586465
[TBL] [Abstract][Full Text] [Related]
17. Calpain-dependent proteolysis of NF2 protein: involvement in schwannomas and meningiomas.
Kimura Y; Saya H; Nakao M
Neuropathology; 2000 Sep; 20(3):153-60. PubMed ID: 11132929
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations.
Ladeiro Y; Couchy G; Balabaud C; Bioulac-Sage P; Pelletier L; Rebouissou S; Zucman-Rossi J
Hepatology; 2008 Jun; 47(6):1955-63. PubMed ID: 18433021
[TBL] [Abstract][Full Text] [Related]
19. New insight into the role of miRNAs in leukemia.
Zhang H; Chen Y
Sci China C Life Sci; 2009 Mar; 52(3):224-31. PubMed ID: 19294347
[TBL] [Abstract][Full Text] [Related]
20. Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas.
Sainz J; Huynh DP; Figueroa K; Ragge NK; Baser ME; Pulst SM
Hum Mol Genet; 1994 Jun; 3(6):885-91. PubMed ID: 7951231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
